{
    "ticker": "HOTH",
    "name": "Hoth Therapeutics, Inc.",
    "description": "Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with unmet medical needs, particularly in the dermatology field. Founded in 2018 and headquartered in New York City, the company aims to address chronic skin conditions, with a primary focus on developing treatments for atopic dermatitis and other skin disorders that significantly impact the quality of life for those affected. Hoth's lead product candidate, HT-001, is a topical treatment designed to alleviate symptoms associated with atopic dermatitis, and the company is also exploring additional indications in the dermatological space. Hoth leverages advanced drug delivery systems and formulations to enhance the effectiveness and patient experience of its treatments. The company's mission is to provide safe and effective solutions to improve the lives of patients suffering from chronic skin conditions while advancing the science of dermatology through innovative research and development. Hoth Therapeutics is committed to working closely with healthcare professionals and regulatory bodies to bring its therapies from the laboratory to market, ensuring compliance and safety at every step of the process.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2018",
    "website": "https://www.hoththerapeutics.com",
    "ceo": "Roberta D. Siddiqui",
    "social_media": {
        "twitter": "https://twitter.com/HothTherapeutics",
        "linkedin": "https://www.linkedin.com/company/hoth-therapeutics/"
    },
    "investor_relations": "https://www.hoththerapeutics.com/investors",
    "key_executives": [
        {
            "name": "Roberta D. Siddiqui",
            "position": "CEO"
        },
        {
            "name": "David A. Fater",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Dermatology Treatments",
            "products": [
                "HT-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hoth Therapeutics, Inc. | Innovative Dermatology Solutions",
        "meta_description": "Hoth Therapeutics, Inc. is dedicated to developing innovative therapeutics for chronic skin conditions. Learn about our mission and product pipeline.",
        "keywords": [
            "Hoth Therapeutics",
            "Biotechnology",
            "Pharmaceuticals",
            "Dermatology",
            "Atopic Dermatitis",
            "HT-001"
        ]
    },
    "faq": [
        {
            "question": "What is Hoth Therapeutics known for?",
            "answer": "Hoth Therapeutics is known for developing innovative treatments for chronic skin conditions, particularly atopic dermatitis."
        },
        {
            "question": "Who is the CEO of Hoth Therapeutics?",
            "answer": "Roberta D. Siddiqui is the CEO of Hoth Therapeutics, Inc."
        },
        {
            "question": "Where is Hoth Therapeutics headquartered?",
            "answer": "Hoth Therapeutics is headquartered in New York City, New York, USA."
        },
        {
            "question": "What is Hoth's lead product candidate?",
            "answer": "Hoth's lead product candidate is HT-001, a topical treatment for atopic dermatitis."
        },
        {
            "question": "When was Hoth Therapeutics founded?",
            "answer": "Hoth Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "VRTX",
        "REGN",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "CELG"
    ]
}